BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

FlowCardia, Inc. Announces Final Enrollment in the PATRIOT Peripheral Study With the CROSSER(TM) Family of CTO Recanalization Catheters


9/12/2007 9:58:02 AM

SUNNYVALE, Calif., Sept. 12 /PRNewswire/ -- FlowCardia, Inc., a medical device company developing a portfolio of endovascular devices for the treatment of coronary and peripheral chronic total occlusions (CTOs), announced the completion of enrollment into the PATRIOT pivotal study. FlowCardia's 8 hospital, 85 patient U.S. PATRIOT (Peripheral Approach To Recanalization In Occluded Totals) Study was designed to assess the safety and efficacy of the peripheral line of CROSSER Catheters in lower limb CTOs.

The CROSSER(TM) is a rapid exchange catheter delivered over standard .014" and .018" guidewires to the site of a CTO. Utilizing high frequency vibration, the CROSSER Catheter is designed to safely and quickly cross CTOs allowing for subsequent debulking, balloon angioplasty and stent placement. The CROSSER(TM) 14P, CROSSER(TM) 14S and CROSSER(TM) 18 Catheters were studied in the PATRIOT Trial.

Dr. Jim Joye, the PATRIOT Study principle investigator commented, "We were very pleased with the success of the CROSSER in the PATRIOT Study. The device worked well in the upper leg and also proved safe and effective crossing the more difficult, below the knee occlusions. This new endovascular line of catheters will help us cross lesions that previously could only be treated with a more invasive open surgery."

"We are very pleased with the results from the PATRIOT Study," said Wick Goodspeed, President and CEO of FlowCardia. "Having 3 CROSSER Catheter models for use in the study allowed physicians to choose the appropriate Catheter based on vessel size and CTO location. The CROSSER family delivered a simple, safe and effective solution for crossing CTOs in the legs."

FlowCardia, Inc. is a privately held medical device company established in 2002 to design and manufacture a safe and effective CTO recanalization system. Additional information is available on the Company's Web Site at http://www.flowcardia.com.

CONTACT: Mark Page Sr. Director, Worldwide Marketing & International Sales FlowCardia, Inc. 408-617-0352

FlowCardia, Inc.

CONTACT: Mark Page, Sr. Director, Worldwide Marketing & InternationalSales of FlowCardia, Inc., +1-408-617-0352



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES